Alimera Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Alimera Sciences wird ein Gewinn- und Umsatzwachstum von 61% bzw. 17.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 63.9% pro Jahr wachsen soll.

Wichtige Informationen

61.0%

Wachstumsrate der Gewinne

63.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	16.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Oct 06

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Sep 20

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Aug 09

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Jul 22

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Jul 08

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Mar 24

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Nov 06

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Aug 24

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Feb 11

Alimera Sciences (ALIM) Investor Presentation - Slideshow

Nov 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ALIM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	136	24	52	N/A	3
12/31/2025	121	10	37	N/A	4
12/31/2024	106	-3	32	N/A	4
3/31/2024	90	-23	-88	-13	N/A
12/31/2023	81	-21	-90	-14	N/A
9/30/2023	68	-21	-94	-18	N/A
6/30/2023	59	-25	-86	-10	N/A
3/31/2023	56	-17	-6	-6	N/A
12/31/2022	54	-18	-10	-10	N/A
9/30/2022	54	-18	-15	-14	N/A
6/30/2022	53	-17	-16	-15	N/A
3/31/2022	60	-7	-8	-7	N/A
12/31/2021	59	-4	-4	-3	N/A
9/30/2021	59	-1	1	1	N/A
6/30/2021	59	2	1	2	N/A
3/31/2021	47	-8	-6	-5	N/A
12/31/2020	51	-5	-3	-2	N/A
9/30/2020	54	-4	-2	-2	N/A
6/30/2020	55	-6	-4	-3	N/A
3/31/2020	56	-9	-4	-4	N/A
12/31/2019	54	-10	-4	-4	N/A
9/30/2019	52	-12	-4	-4	N/A
6/30/2019	50	19	-4	-4	N/A
3/31/2019	50	22	-6	-6	N/A
12/31/2018	47	17	-12	-12	N/A
9/30/2018	41	11	-14	-14	N/A
6/30/2018	39	-22	-14	-14	N/A
3/31/2018	39	-23	-14	-14	N/A
12/31/2017	36	-22	N/A	-13	N/A
9/30/2017	37	-21	N/A	-14	N/A
6/30/2017	36	-25	N/A	-18	N/A
3/31/2017	35	-29	N/A	-23	N/A
12/31/2016	34	-33	N/A	-25	N/A
9/30/2016	29	-38	N/A	-32	N/A
6/30/2016	28	-30	N/A	-32	N/A
3/31/2016	24	-32	N/A	-37	N/A
12/31/2015	22	-31	N/A	-45	N/A
9/30/2015	18	-30	N/A	-46	N/A
6/30/2015	14	-35	N/A	-42	N/A
3/31/2015	10	-26	N/A	-33	N/A
12/31/2014	8	-37	N/A	-24	N/A
9/30/2014	8	-41	N/A	-25	N/A
6/30/2014	6	-36	N/A	-29	N/A
3/31/2014	4	-58	N/A	-34	N/A
12/31/2013	2	-51	N/A	-38	N/A
9/30/2013	1	-42	N/A	-35	N/A
6/30/2013	0	-46	N/A	-30	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALIM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ALIM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ALIM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ALIMDie Einnahmen des Unternehmens (17.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ALIMDie Einnahmen des Unternehmens (17.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ALIM in 3 Jahren voraussichtlich hoch sein wird

Alimera Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date pushed back to 2025

Price target increased by 14% to US$8.00

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Recent updates

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Alimera Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Forecast breakeven date pushed back to 2025

Price target increased by 14% to US$8.00

Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Alimera Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Alimera Sciences, Inc. Appoints Todd Wood as President of U.S. Operations

Alimera Sciences, Inc Appoints Maggie A. Pax to its Board of Directors

Alimera Announces Scientific Data Highlighting ILUVIEN to Be Presented at the American Academy of Ophthalmology

Third quarter 2023 earnings released: US$0.06 loss per share (vs US$0.75 loss in 3Q 2022)

Alimera Sciences, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Alimera Sciences, Inc. Announces Management Appointments

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

New major risk - Shareholder dilution

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alimera Sciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Alimera Sciences, Inc., Annual General Meeting, Aug 01, 2023

Forecast breakeven date moved forward to 2024

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alimera Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Less than half of directors are independent

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

Alimera Sciences, Inc. Appoints Russell L. Skibsted as Senior Vice President

Alimera Sciences, Inc. Announces Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN®Administration

Price target decreased to US$10.50

Insufficient new directors

Alimera Sciences, Inc. Announces Resignation of J. Philip Jones as CFO, Effective from November 28, 2022

Alimera Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alimera Sciences, Inc. Announces Paladin Phase 4 Study Confirms ILUVIEN Patients' Reduced Need for Multiple Treatments

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences, Inc. Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Insufficient new directors

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alimera Sciences, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences, Inc., Annual General Meeting, Jul 12, 2022

Alimera Sciences, Inc. Announces that Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN Use for IOP Outcomes

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2024

Alimera Sciences, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$13.00

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Consensus EPS estimates fall by 93%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Alimera Sciences, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

President recently bought US$125k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.12 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN for DME in Belgium

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS US$1.03 (vs US$0.51 loss in 2Q 2020)

Independent Director Mary Szela has left the company

First quarter 2021 earnings released: US$0.63 loss per share (vs US$0.24 loss in 1Q 2020)